Search - tctmd.com

Presenter: Ana Laynez, Rebecca Torguson, Camille Hauville, Gabriel Sardi, Itsik Ben-Dor, Gabriel Maluenda, Michael A. Gaglia, Manuel A. Gonzalez, Israel M. Barbash, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Advertisement

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Datos de Registro Revelan el Ascenso y Caída de la Bivalirudina frente a la Heparina en la Realización de PCI Primarias

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

Safety and Efficacy for the Use of Prasugrel in Patients Undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content